What is Mounjaro made of, and why does the formula matter?

Tirzepatide: the active molecule and what makes it unusual

Tirzepatide is a 39-amino-acid synthetic peptide, engineered to bind two receptors that natural gut hormones bind separately. GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) are both released after eating; they signal to the pancreas, the brain and the gut. Most injectable weight-loss medicines target GLP-1 alone. Tirzepatide was designed from the ground up to activate both, which is why you'll see it described as a dual GIP and GLP-1 receptor agonist.

The practical upshot is that tirzepatide slows gastric emptying, reduces appetite and influences blood-sugar regulation through two complementary pathways rather than one. The NHS medicines page for tirzepatide sets out the mechanism clearly if you want the patient-level detail alongside this explanation.

The molecule is attached to a fatty-acid chain that extends its half-life, so one injection per week is enough to keep it active. This is a deliberate structural choice, not incidental, without that modification the peptide would clear the bloodstream in minutes. For more on how the chemistry connects to Mounjaro's origins as a medicine, the history of what Mounjaro was originally developed for fills in that context.

Excipients: the inactive ingredients that hold the formula together

A medicine is never just its active ingredient. The full Mounjaro formulation, as listed in the Summary of Product Characteristics on the electronic Medicines Compendium (eMC), includes several excipients: sodium phosphate dibasic heptahydrate and sodium phosphate monobasic monohydrate (buffering agents that keep the solution at a stable pH), sodium chloride (to match the osmolarity of body fluids), polysorbate 80 (a surfactant that prevents the peptide from aggregating or sticking to the pen's inner surfaces), and water for injections as the solvent. Hydrochloric acid and sodium hydroxide may be used to adjust pH during manufacture.

None of these are active drugs. Their job is consistency: ensuring that every dose from every pen contains the same concentration of tirzepatide in a stable, injectable form. If you want to check the exact listed excipients on the current approved product, the eMC is the right place, the leaflet inside your pen also lists them.

One quick check worth doing: if your pen looks cloudy, discoloured or contains visible particles, do not use it. The solution should be clear to slightly yellow. That visual check takes about ten seconds and is noted in the Patient Information Leaflet for good reason.

UK strengths and what the dose numbers refer to

Mounjaro is available in the UK at six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg. Each figure is the amount of tirzepatide per weekly dose, not the volume of liquid in the pen, which is the same across all strengths. A prescriber typically starts treatment at 2.5 mg because the first pen's job is to let your system adjust to the medicine, not to deliver the full therapeutic effect straight away.

Eli Lilly manufactures and markets Mounjaro; you can read more about the company behind the pen on the Mounjaro manufacturer page. The full Mounjaro overview covers the UK licence, eligibility criteria and what the SURMOUNT-1 trial data actually showed at higher doses, useful if you're trying to decide whether this medicine is worth exploring.

What you won't find in the formulation: no hormones, no stimulants, no animal-derived insulin and no controlled substances. Tirzepatide is a synthetic peptide made in a laboratory, which is relevant both practically and for people asking whether the pen contains anything they'd want to flag to a clinician before starting.

Does knowing the ingredients change whether Mounjaro is right for you?

Understanding what a medicine is made of is a reasonable starting point, but it's only part of the picture. Whether tirzepatide is suitable for a specific person depends on their full medical history, current medicines and circumstances, all things a prescriber works through at consultation. Polysorbate 80 allergy, for instance, is a genuine contraindication listed in the SmPC. For anyone on oral contraceptives, there's a well-documented interaction worth knowing: because tirzepatide slows gastric emptying, absorption of the pill may be reduced, and NHS guidance recommends adding a non-oral method for the first four weeks of treatment and for four weeks after each dose increase.

If you're weighing up cost alongside clinical fit, the Mounjaro pricing context page explains how UK private treatment is structured. For people curious about how tirzepatide compares formulation-to-formulation with semaglutide, the tirzepatide ingredient breakdown goes deeper on the chemistry side.

Mounjaro is a prescription-only medicine. A GPhC-registered prescriber at nume reviews every consultation personally before any treatment is considered. If you'd like to find out whether you're eligible, check your eligibility through a free consultation.